Episodebeskrivelse
Episode 167 — 14 November 2026
Examining HCA's profit warning as a signal of access erosion, subcutaneous Leqembi's implications, FTC's insulin settlement impact, and ICER's early-phase advice expansion.
Hosted by Marcus and Sara.
Access Brief — Daily briefings on HEOR, HTA strategy and the evidence access landscape.
Full transcript and sources at outcomes-analytica.no/podcast

